GIG CYMRU NHS WALES | Cyd-bwyllgor Comisiynu Joint Commissioning Committee

# Blueteq Forms Live

02/02/2026

**Notice:** We are currently reviewing our list of providers. If you require any additional information, please contact us directly at NWJCCBlueteq@wales.nhs.uk.

| Medicine Generic Name | Reference | Indication | Age Range | Initiation Form | Continuation Form | NWJCC Directorate | Policy |
|---|---|---|---|---|---|---|---|
| **Adalimumab (M4C)** | **TA186** | Treatment of severe active Crohn's disease in children aged 2-5 years old | 2-5 years | Live | Live | Women & Children | In development |
| **Adalimumab (M4C)** | **TA187** | Treatment of severe active Crohn's disease in children aged 6-17 years old | 6-17 years | Live | Live | Women & Children | In development |
| **Adalimumab (M4C)** | **TA329** | Treatment of moderate to severe active ulcerative colitis after the failure of conventional therapy in children aged 2-5 years old | 2-5 years | Live | Live | Women & Children | In development |
| **Adalimumab (M4C)** | **TA329** | Treatment of moderate to severe active ulcerative colitis after the failure of conventional therapy in children aged 6-17 years old | 6-17 years | Live | Live | Women & Children | In development |
| **Agalsidase alfa** | **AWMSG 11** | Long-term enzyme replacement therapy in patients with a confirmed diagnosis of Fabry Disease (α-galactosidase A deficiency) | 18-99 years | Live | Live | Women & Children | CP55 |
| **Agalsidase beta** | **AWMSG 12** | Long-term enzyme replacement therapy in patients with a confirmed diagnosis of Fabry Disease (α-galactosidase A deficiency) | 18-99 years | Live | Live | Women & Children | CP55 |
| **Alglucosidase alfa** | **AWMSG 17** | Long term enzyme replacement therapy in patients with a confirmed diagnosis of Pompe disease (acid α-glucosidase deficiency) | 0-99 years | Live | Live | Women & Children | CP55 |
| **Anakinra** | **TA685** | Treatment for systemic juvenile idiopathic arthritis in people 8 months or older | 8 months-17 years | Live | Live | Women & Children | In development |
| **Anhydrous sodium thiosulfate** | **TA1034** | Prevention of hearing loss caused by cisplatin chemotherapy in people 1 month to 17 years with localised solid tumours | 1 month-17 years | Live | Not applicable | Women & Children | PPS315 |
| **Asfotase alfa** | **HST23** | Treatment of paediatric-onset hypophosphatasia in babies, children, young people and adults | 0-99 years | Live | Not applicable | Women & Children | PP156 |
| **Ataluren** | **HST22 / AWMSG 3911** | Treatment of Duchenne muscular dystrophy with a nonsense mutation in the dystrophin gene in people 2 years and over who can walk | 2-17 years | Live | Live | Women & Children | PP118 |
| **Avalglucosidase alfa** | **TA821** | Treatment of Pompe disease | 0-99 years | Live | Live | Women & Children | CP55 |
| **Belimumab** | **TA752** | Treatment of active autoantibody-positive systemic lupus erythematosus | 5-17 years | Live | Live | Women & Children | PPS317 |
| **Belumosudil** | **TA949** | Treatment of chronic graft versus host disease after 2 or more lines of systemic therapy | 12-17 years | Live | Live | Women & Children | In development |
| **Berotralstat** | **TA738** | Prevention of recurrent attacks of hereditary angioedema in people 12 years and over | 12-99 years | Live | Live | Cancer and Blood | PP236 |
| **Birch bark extract** | **HST28** | Treatment of skin wounds associated with dystrophic and junctional epidermolysis bullosa | 6 months-99 years | Live | Live | Women & Children | PPS284 |
| **Blinatumomab (M4C)** | **TA589** | Treatment of patients in first complete haematological complete remission and with minimal residual disease post 1st line induction chemotherapy in B-precursor acute lymphoblastic leukaemia in CHILD patients. | 1-17 years | Live | Not applicable | Women & Children | M4C |
| **Burosumab** | **TA993** | Treatment of X-linked hypophosphataemia in adults | 18-99 years | Live | Live | Women & Children | In development |
| **Burosumab** | **HST8** | Treatment of X-linked hypophosphataemia in children and young people | 1-17 years | Live | Live | Women & Children | PP177 |
| **Canakinumab** | **Policy** | Treatment of periodic fever syndromes: TRAPS, HIDS/MKD and FMF in people aged 2 years and older | 2-99 years | Live | Live | Women & Children | PP228 |
| **Cannabidiol** | **TA873** | Adjunctive therapy of seizures associated with tuberous sclerosis complex (TSC) for patients 2 years of age and older | 2-17 years | Live | Live | Cancer and Blood | PP272 |
| **Cannabidiol** | **TA614** | Adjuvant treatment of seizures associated with Dravet syndrome in people aged 2 years and older | 2-17 years | Live | Live | Women & Children | PPS203 |
| **Cannabidiol** | **TA615** | Adjuvant treatment of seizures associated with Lennox-Gastaut syndrome in people aged 2 years and older | 2-17 years | Live | Live | Women & Children | PPS203 |
| **Cerliponase alfa** | **HST12** | Treatment of neuronal ceroid lipofuscinosis type 2 in children | 0-17 years | Live | Live | Women & Children | PP262 |
| **Cipaglucosidase alfa with Migliustat** | **TA912** | Treatment of late-onset Pompe disease in adults | 18-99 years | Live | Live | Women & Children | CP55 |
| **Crovalimab** | **TA1019** | Treating Paroxysmal nocturnal haemoglobinuria | 18-99 years | Live | Live | Cancer and Blood | In development |
| **Danicopan as an add-on treatment to a C5 inhibitor** | **TA1010** | Extravascular haemolysis in adults with paroxysmal nocturnal haemoglobinuria | 18-99 years | Live | Live | Cancer and Blood | In development |
| **Danicopan as an add-on treatment to a C5 inhibitor (M4C)** | **TA1010** | Extravascular haemolysis in adults with paroxysmal nocturnal haemoglobinuria | 12-17 years | Live | In development | Cancer and Blood | M4C |
| **Dexrazoxane** | **Policy** | Prevention of cardiotoxicity in children aged 16 years and under receiving high-dose anthracyclines or related drugs for the treatment of cancer | 0-17 years | Live | In development | Women & Children | PP253 |
| **Eculizumab** | **AWMSG 0509** | Treatment of paroxysmal nocturnal haemoglobinuria in paediatric patients with a body weight of 5kg or above | 0-99 years | Live | Live | Cancer and Blood | CP152 |
| **Eculizumab** | **HST1** | Treatment of atypical haemolytic uraemic (aHUS) syndrome in adults and children | 0-99 years | Live | Live | Renal | In development |
| **Efanesoctocog alfa** | **TA1051** | Treatment and prevention of bleeding episodes in haemophilia A in people 2 years and over | 2-99 years | Live | In development | In development | In development |
| **Eladocagene exuparvovec** | **HST26** | Treatment of aromatic L-amino acid decarboxylase deficiency | 18 months-99 years | Live | Not applicable | Women & Children | PP281 |

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| **Eliglustat** | **HST5** | Treatment of Type 1 Gaucher disease | 18-99 years | Live | Live | Women & Children | CP55 |
| **Elosulfase alfa** | **HST19** | Treatment of mucopolysaccharidosis type 4A in people of all ages | 0-99 years | Live | Live | Women & Children | CP55 |
| **Eplontersen** | **TA1020** | Treatment of hereditary transthyretin-related amyloidosis | 18-99 years | Live | Live | Neurosciences, Long Term Contitions & Rare Diseases | PP187 |
| **Everolimus** | **AWMSG 2142** | Adjunctive treatment of patients aged 2 years and older whose refractory partial-onset seizures, with or without secondary generalisation, are associated with tuberous sclerosis complex (TSC) | 2-17 years | Live | Live | Cancer and Blood | PP250 |
| **Everolimus** | **AWMSG 1156** | Treatment of adult and paediatric patients with subependymal giant cell astrocytoma (SEGA) associated with TSC who require therapeutic intervention but are not amenable to surgery | 2-99 years | Live | In development | Cancer and Blood | PP273 |
| **Everolimus** | **AWMSG 1156** | Treatment of adult patients with renal angiomyolipoma associated with tuberous sclerosis complex who are at risk of complications (based on factors such as tumour size or presence of aneurysm, or presence of multiple or bilateral tumours) but who do not require immediate surgery | 18-99 years | Live | Live | Cancer and Blood | PP274 |
| **Evinacumab** | **TA1002** | Treatment of homozygous familial hypercholesterolaemia in people 12 years and over | 12-99 years | Live | Live | Women & Children | PPS308 |
| **Evinacumab (M4C)** | **TA1002** | Treatment of homozygous familial hypercholesterolaemia | 5-11 years | Live | Live | Women & Children | M4C |
| **Fenfluramine** | **TA808** | Treatment of  seizures associated with Dravet syndrome in people aged 2 and older | 2-17 years | Live | Live | Women & Children | PPS203 |
| **Fenfluramine** | **TA1050** | Treatment of seizures associated with Lennox–Gastaut syndrome in people aged 2 and older | 2-17 years | Live | Live | Women & Children | PPS203 |
| **Givosiran** | **HST16** | Treatment of acute hepatic porphyria | 12-99 years | Live | Live | Neurosciences, Long Term Contitions & Rare Diseases | PP252 |
| **Glycerol Phenylbutyrate** | **AWMSG 2127** | Glycerol Phenylbutyrate for for use as an adjunctive therapy for chronic management of patients with urea cycle disorders including deficiencies | 0-99 years | Live | Live | Women & Children | In development |
| **Imiglucerase** | **Policy** | Treatment of Gaucher disease Type 1 | 18-99 | Live | Live | Women & Children | CP55 |
| **Imlifidase** | **TA809** | Desensitisation treatment before kidney transplant in people with chronic kidney disease | 18-99 years | Live | In development | Renal | PPS256 |
| **Imlifidase (M4C)** | **TA809** | Treatment of desensitisation treatment before kidney transplant in people with chronic kidney disease | Post-pubescent | Live | In development | In development | M4C |
| **Infliximab (M4C)** | **TA187** | Treatment of severe active Crohn's disease | 6-17 years | Live | Live | Women & Children | In development |
| **Inotersen** | **HST9** | Treatment of hereditary transthyretin-related amyloidosis | 16-99 years | Live | Live | Neurosciences, Long Term Contitions & Rare Diseases | PP187 |
| **Iptacopan** | **TA1000** | Treatment of paroxysmal nocturnal haemoglobinuria in adults | 18-99 years | Live | Live | Cancer and Blood | In development |
| **Laronidase** | **AWMSG 180** | Treatment of mucopolysaccharidosis type I | 0-99 years | Live | Live | Women & Children | CP55 |
| **Leniolisib** | **HST33** | Treatment of activated phosphoinositide 3-kinase delta syndrome in people 12 years and over | 12-99 years | Live | Live | Neurosciences, Long Term Contitions & Rare Diseases | In development |
| **Letermovir** | **TA591** | Prevention of cytomegalovirus disease after a stem cell transplant | 0-17 years | Live | In development | Women & Children | NA |
| **Lumasiran** | **HST25** | Treatment of primary hyperoxaluria type 1 in people of all ages | 0-99 years | Live | Live | Women & Children | PP277 |
| **Lutetium (177Lu) oxodotreotide** | **TA539** | Treatment of unresectable or metastatic neuroendocrine tumours in adults | 16-99 years | Live | Not applicable | Cancer and Blood | PP195 |
| **Mepolizumab** | **AWMSG 3750 / TA671** | Treatment of severe refractory eosinophilic asthma in adolescents and children aged 6 years and older | 6-17 years | Live | Live | Women & Children | In development |
| **Mercaptamine bitartrate** | **AWMSG 0922** | Treatment of proven nephropathic cystinosis. Mercaptamine reduces cystine accumulation in some cells (e.g. leukocytes, muscle and liver cells) of nephropathic cystinosis patients and, when treatment is started early, it delays the development of renal failure | 0-99 years | Live | Live | Women & Children | CP55 |
| **Migalastat** | **HST4** | Treatment of Fabry disease | 18-99 years | Live | Live | Women & Children | CP55 |
| **Migalastat** | **AWMSG 4268** | Treatment of Fabry disease | 12-17 years | Live | Live | Women & Children | CP55 |
| **Miglustat** | **AWMSG 371** | Treatment of progressive neurological manifestations in adult patients and paediatric patients with Niemann-Pick type C disease | 0-99 years | Live | Live | Neurosciences, Long Term Contitions & Rare Diseases | CP55 |
| **Mirikizumab (M4C)** | **TA1080** | Treatment of moderately to severly active Crohn's disease | 12-17 years | Live | Live | Women & Children | M4C |
| **Mirikizumab (M4C)** | **TA925** | Treatment of  moderately to severely active ulcerative colitis | 12-17 years | Live | Live | Women & Children | M4C |
| **Nirsevimab** | **(WHC/2025/029)** | To reduce the risk of respiratory syncytial virus (RSV) in infants with severe combined immunodeficiency syndrome (SCID) | 0-2 years | Live | Not applicable | Women & Children | As per Green Book |
| **Nirsevimab** | **(WHC/2025/029)** | To reduce the risk of respiratory syncytial virus (RSV) in infants with respiratory disease | 0-1 years | Live | Not applicable | Women & Children | As per Green Book |
| **Nirsevimab** | **(WHC/2025/029)** | To reduce the risk of respiratory syncytial virus (RSV) in infants with congenital heart disease | 0-1 years | Live | Not applicable | Women & Children | As per Green Book |
| **Nusinersen** | **TA588** | Treatment of spinal muscular atrophy | 0-17 years | Live | Live | Women & Children | PP191 |
| **Ocrelizumab (M4C)** | **TA585** | Treatment of primary progressive multiple sclerosis | Post-pubescent | Live | Live | Women & Children | M4C |

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| **Ocrelizumab (M4C)** | **TA533** | Treatment of relapsing-remitting multiple sclerosis | Post-pubescent | Live | Live | Women & Children | M4C |
| **Odevixibat** | **HST17** | Treatment of progressive familial intrahepatic cholestasis (PFIC) in patients aged 6 months or older | 6 months-17 years | Live | Live | Neurosciences, Long Term Contitions & Rare Diseases | PP249 |
| **Patisiran** | **HST10** | Treatment of hereditary transthyretin amyloidosis | 16-99 years | Live | Live | Neurosciences, Long Term Contitions & Rare Diseases | PP187 |
| **Pegcetacoplan** | **TA778** | Treatment of Paroxysmal nocturnal haemoglobinuria | 18-99 years | Live | In development | Cancer and Blood | In development |
| **Pegunigalsidase alfa** | **TA915** | Treatment of adults with Fabry disease | 18-99 years | Live | Live | Women & Children | CP55 |
| **Ravulizumab** | **TA698** | Treatment of paroxysmal nocturnal haemoglobinuria | 18-99 years | Live | Live | Cancer and Blood | In development |
| **Ravulizumab** | **AWMSG 4869** | Treatment of paediatric patients with a body weight of 10 kg or above with paroxysmal nocturnal haemoglobinuria (PNH) | 0-17 years | Live | Live | Women & Children | In development |
| **Ravulizumab** | **TA710** | Treatment of atypical haemolytic uraemic (aHUS) syndrome in adults and children | 0-99 years | Live | Live | Renal | In development |
| **Risankizumab (M4C)** | **TA888** | Treatment of moderately to severely active Crohn's disease | Post-pubescent | Live | Live | Women & Children | M4C |
| **Risdiplam** | **TA755** | Treatment of spinal muscular atrophy in children and adults (NWJCC commissioned in Paeds Only) | 0-17 years | Live | Live | Women & Children | PP240 |
| **Ruxolitinib** | **TA1054** | Treatment of acute graft versus host disease that responds inadequately to corticosteroids in people 12 years and over | 12-99 years | Live | Not applicable | Cancer and Blood | In development |
| **Ruxolitinib (M4C)** | **TA1054** | Treatment of acute graft versus host disease that responds inadequately to corticosteroids | 2-11 years | Live | Not applicable | Cancer and Blood | M4C |
| **Sapropterin dihydrochloride** | **TA729** | Treatment of hyperphenylalaninaemia (HPA) in phenylketonuria (PKU) and tetrahydrobiopterin (BH4) disorders | 0-99 years | Live | Live | Women & Children | PP223 |
| **Sebelipase alfa** | **HST30** | Treatment of Wolman Disease. *Patient must be aged 2 years or younger when treatment was initiated. | 0-17 years | Live | Live | Women & Children | CP55 |
| **Selpercatinib** | **TA1038** | Treatment of advanced thyroid cancer with RET alterations after treatment with a targeted cancer drug in people 12 years and over | 12-17 years | Live | Not applicable | Cancer and Blood | In development |
| **Selumetinib** | **HST20** | Treatment of symptomatic and inoperable plexiform neurofibromas associated with type 1 neurofibromatosis in children aged 3 years and over | 3-99 years | Live | Live | Neurosciences, Long Term Contitions & Rare Diseases | PP267 |
| **Setmelanotide** | **HST31** | Treatment obesity and hyperphagia in Bardet-Biedl syndrome (patients aged 6-17 years when treatment starts) | 6-99 years | Live | Live | Women & Children | PPS289 |
| **Somapacitan** | **TA1066** | Treatment of growth hormone deficiency in people 3 to 17 years | 3-17 years | Live | Live | Women & Children | In development |
| **Somatrogon** | **TA863** | Growth disturbance in children and young people aged 3 years and over | 3-17 years | Live | Live | Women & Children | In development |
| **Somatropin** | **TA188** | Treatment of growth failure in children | 0-17 years | Live | Live | Women & Children | In development |
| **Tafamidis** | **TA984** | Treatment of transthyretin amyloidosis with cardiomyopathy in adults | 16-99 years | Live | Live | Neurosciences, Long Term Contitions & Rare Diseases | PPS306 |
| **Teduglutide** | **TA804** | Treatment of Short bowel syndrome in people 1 year and above | 1-99 years | Live | Live | Neurosciences, Long Term Contitions & Rare Diseases | PP265 |
| **Teriflunomide** | **TA303 / 4033** | Treatment of relapsing-remitting multiple sclerosis in children aged 10-17 years | 10-17 years | Live | Live | Women & Children | NA |
| **Tezepelumab** | **TA880** | Treatment of severe asthma | 12-17 years | Live | Live | Women & Children | NA |
| **Tofacitinib** | **TA735** | Treatment of Juvenile idiopathic arthritis | 2-17 years | Live | Live | Women & Children | PP229 |
| **Tofacitinib (M4C)** | **TA547** | Treatment of moderately to severely active ulcerative colitis in children | 2-17 years | Live | Live | Women & Children | M4C |
| **Upadacitinib (M4C)** | **TA856** | Treatment of moderately to severely active ulcerative colitis | 12-17 years | Live | Live | Women & Children | M4C |
| **Upadacitinib (M4C)** | **TA905** | Treatment of previously treated moderately to severely active Crohn's disease | 12-17 years | Live | Live | In development | M4C |
| **Ustekinumab** | **OW25** | Treatment of inflammatory bowel disease (ulcerative colitis and Crohn's disease) in children | 6-17 years | Live | Live | Women & Children | In development |
| **Vamorolone** | **TA1031** | Treatment of Duchenne muscular dystrophy in people 4 years and over. | 4-17 years | Live | Live | Women & Children | In development |
| **Vedolizumab** | **OW24** | Treatment of inflammatory bowel disease (ulcerative colitis and Crohn's disease) in children | 6-17 years | Live | Live | Women & Children | In development |
| **Velaglucerase alfa** | **Policy** | Treatment of Type 1 Gaucher disease | 18-99 years | Live | Live | Women & Children | CP55 |
| **Volanesorsen** | **HST13** | Treatment of Familial chylomicronaemia syndrome in adults | 18-99 years | Live | Live | Women & Children | PP217 |
| **Volanesorsen (M4C)** | **HST13** | Treatment of Familial chylomicronaemia syndrome in adults | 16-99 years | Live | Live | Women & Children | M4C |
| **Vonicog alfa** | **OW19** | Treatment and prevention of bleeding in adults and children with von Willebrand disease | 0-99 years | Live | Live | Cancer and Blood | PP215 |

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| **Voretigene neparvovec** | **HST11** | Treatment of Inherited retinal dystrophies caused by RPE65 gene mutations in adults and children | 16-99 years | Live | In development | Cardiac | PP196 |
| **Vutrisiran** | **TA868** | Treatment of hereditary transthyretin-related amyloidosis | 18-99 years | Live | Live | Neurosciences, Long Term Contitions & Rare Diseases | PP187 |
| **Axicabtagene ciloleucel** | **TA872** | Treatment diffuse large B-cell lymphoma and primary mediastinal large B-cell lymphoma after 2 or more systemic therapies | 18-99 years | Live (a+b) | Not applicable | Cancer and Blood | CP175 |
| **Axicabtagene ciloleucel** | **TA895** | Treatment of relapsed or refractory diffuse large B-cell lymphoma after first-line chemoimmunotherapy | 18-99 years | Live (a+b) | Not applicable | Cancer and Blood | In development |
| **Brexucabtagene autoleucel** | **TA893** | Treatment of relapsed or refractory B-cell acute lymphoblastic leukaemia in people 26 years and over | 26-99 years | Live (a+b) | Not applicable | Cancer and Blood | In development |
| **Brexucabtegene (Formerly KTE-X19)** | **TA677** | Treatment of Relapsed or refractory mantle cell lymphoma | 16-99 years | Live (a+b) | Not applicable | Cancer and Blood | In development |
| **Lisocabtegene maraleucel** | **TA1048** | Treatment of relapsed or refractory large B-cell lymphoma after first-line chemoimmunotherapy when a stem cell transplant is suitable | 18-99 years | Live (a+b) | Not applicable | In development | In development |
| **Onasemnogene abeparvovec** | **HST15** | Treatment of Spinal muscular atrophy type 1 | 0-12 months | Live (a+b) | Not applicable | Cancer and Blood | In development |
| **Onasemnogene abeparvovec** | **HST24** | Treatment of presymptomatic spinal muscular atrophy in babies 12 months and under | 0-12 months | Live (a+b) | Not applicable | Cancer and Blood | In development |
| **Tisagenlecleucel-T** | **TA554** | Treatment of Relapsed or refractory B-cell acute lymphoblastic leukaemia in people up to 25 years | 0-25 years | Live (a+b) | Not applicable | Cancer and Blood | PP185 |
| **Atidarsagene autotemcel** | **HST18** | Treatment of metachromatic leukodystrophy in children | 0-17 years | Live (a+b+c) | Not applicable | Women & Children | PP257 |
| **Etranacogene dezaparvovec** | **TA989** | Treatment of moderately severe or severe haemophilia B | 18-99 years | Live (a+b+c) | Not applicable | Cancer and Blood | In development |
| **Exagamglogene autotemcel** | **TA1003** | Treatment of transfusion-dependent beta-thalassaemia in people 12 years and over | 12-99 years | Live (a+b+c) | Not applicable | Cancer and Blood | In development |
| **Exagamglogene autotemcel** | **TA1044** | Treatment of severe sickle cell disease in people 12 years and over | 12-99 years | Live (a+b+c) | Not applicable | Cancer and Blood | In development |
| **Ivacaftor–tezacaftor–elexacaftor, tezacaftor–ivacaftor and lumacaftor–ivacaftor** | **TA988** | Treatment of cystic fibrosis | 2-99 years | Not applicable | Not applicable | In development | PP198 |
| **Nitisinone** | **AWMSG 2322** | Treatment of adult patients with alkaptonuria | 18-99 years | Not applicable | Not applicable | Neurosciences, Long Term Contitions & Rare Diseases | In development |